Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Ebru Karci"'
Autor:
Dilsa Mizrak, Emra Asfuroglu Kalkan, Ali Alkan, Halis Yerlikaya, Elif Berna Koksoy, Ebru Karci, Gungor Utkan, Ahmet Demirkazik
Publikováno v:
Journal of Oncological Sciences, Vol 2, Iss 1, Pp 27-28 (2016)
Background: Hyponatremia is one of the most common electrolyte abnormalities seen in hospitalized patients. In cancer patients, it's generally related to syndrome of inappropriate ADH secretion (SIADH). Case Report: Here, we report a breast cancer pa
Externí odkaz:
https://doaj.org/article/f75bd9443ff947aa8c176667fe6b3cad
Autor:
Bozkaya, Yakup, Özdemir, Nuriye Yıldırım, Erdem, Gökmen Umut, Güner, Ebru Karcı, Ürün, Yüksel, Demirci, Nebi Serkan, Yazıcı, Ozan, Köstek, Osman, Zengin, Nurullah
Publikováno v:
In Journal of Oncological Sciences April 2018 4(1):5-10
Autor:
Mutlu HIZAL, Mehmet Ali Nahit ŞENDUR, Burak BİLGİN, Ebru KARCI GÜNER, Muhammed Bülent AKINCI, Yakup ERGÜN, Ece ESİN, Elif Berna KÖKSOY, Ahmet SEZER, Nuriye ÖZDEMİR, Berna ÖKSÜZOĞLU, Bülent YALÇIN, Güngör UTKAN, Yüksel ÜRÜN
Publikováno v:
Journal of Oncological Sciences. 8:69-75
ABS TRACT Objective: Pancreatic cancer is one of the leading causes of cancer-related death. Despite the introduction of new therapeutic agents, survival rates remain low. Furthermore, few trials have evaluated the options for second-line therapy and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cb55beeaf8886980bb0bc1428a235c69
https://doi.org/10.37047/jos.2022-88853
https://doi.org/10.37047/jos.2022-88853
Publikováno v:
Volume: 5, Issue: 3 337-346
Batı Karadeniz Tıp Dergisi
Batı Karadeniz Tıp Dergisi
menopausal status, and glucose tolerance in endocrinology outpatients.Material and Methods: A total of 178 endocrinology outpatients with oral glucose tolerance test(OGTT) findings were included. Data on anthropometrics [body mass index (BMI), waist
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c7878db284167addcdc9d37db59e7710
https://doi.org/10.29058/mjwbs.838964
https://doi.org/10.29058/mjwbs.838964
Autor:
ebru karci
Publikováno v:
Eurasian Journal of Medical Investigation.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::72b2078e8996ae8e0ee8a24d57345e11
https://doi.org/10.14744/ejmi.2022.19889
https://doi.org/10.14744/ejmi.2022.19889
Autor:
Ebru Karci
Publikováno v:
Eurasian Journal of Medical Investigation.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c779364a24fcd4e36c2899182cf947c0
https://doi.org/10.14744/ejmi.2022.37065
https://doi.org/10.14744/ejmi.2022.37065
Autor:
Yasin Kutlu, Sabin Goktas Aydin, Ahmet Bilici, Bala Basak Oven, Omer Fatih Olmez, Ozgur Acikgoz, Jamshid Hamdard, Ebru Karci
Publikováno v:
SSRN Electronic Journal.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::20bd339bbf2b2a45e06c264b0a2746c5
https://doi.org/10.2139/ssrn.3977779
https://doi.org/10.2139/ssrn.3977779
Autor:
Nuriye Yıldırım Özdemir, Osman Kostek, Yuksel Urun, Nurullah Zengin, Ozan Yazici, Nebi Serkan Demirci, Ebru Karci Guner, Gökmen Umut Erdem, Yakup Bozkaya
Publikováno v:
Journal of Oncological Sciences, Vol 4, Iss 1, Pp 5-10 (2018)
Objective: In this study, our aim was to identify the main predictive factors associated with pathologic complete response (pCR) to neoadjuvantchemoradiotherapy (nCRT) in patients with locally advanced rectal cancer. Methods: The patients who had loc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::575f03b033f308ce05d2b727c7fb275a
https://doi.org/10.1016/j.jons.2017.12.004
https://doi.org/10.1016/j.jons.2017.12.004
Autor:
Yakup, Ergun, Nuriye Yildirim, Ozdemir, Ebru Karci, Guner, Ece, Esin, Mehmet Ali, Sendur, Elif Berna, Koksoy, Nebi Serkan, Demirci, Tulay, Eren, Isa, Dede, Ahmet, Sezer, Huseyin, Engin, Berna, Oksuzoglu, Bulent, Yalcin, Gungor, Utkan, Nurullah, Zengin, Yuksel, Urun
Publikováno v:
Journal of B.U.ON. : official journal of the Balkan Union of Oncology. 23(7)
Gemcitabine is among the standard first-line agents for the treatment of metastatic pancreatic cancer. However, as the median survival with gemcitabine monotherapy is 6 months, different combinations are being studied for better, prolonged survival.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::e60d20186d66a736f91e0296c3e2579b
https://pubmed.ncbi.nlm.nih.gov/30722120
https://pubmed.ncbi.nlm.nih.gov/30722120
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.